long intergenic non-protein coding RNA 2690Genealiases: []
Q-omics provides the consensus-scored LINC02690 profile across patient tissues and cancer cell-line models. LINC02690 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02690 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, LINC02690 RNA expression shows 7,978 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUSC, and TGCT as cancer lineages where LINC02690 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02690 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02690 survival associations across molecular data types. LINC02690 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02690 RNA expression–survival associations across cancer types. High LINC02690 expression shows unfavorable associations in ACC, COAD, THCA and ESCA, but favorable associations in HNSC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02690 RNA expression.
This table summarizes LINC02690 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02690. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02690 shows lower tumor expression in KICH, COAD and KIRC and higher tumor expression in LUSC, LUAD and BRCA. The LUSC box plot shows higher LINC02690 RNA expression in tumor versus normal tissue (log2 FC = +0.150, t-test p < 0.001).
This table shows molecular features associated with LINC02690 in patient tissues and cancer cell lines. In patient samples, LINC02690 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
